Screening Data Exchange Standards

  • 464 views
Uploaded on

David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.

David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.

More in: Technology , Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
464
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
3
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Standards for Exchanging Screening Data Dave Kniaz Merck Research IT, Discovery Pre-Clinical Sciences Director, Business Architecture Pistoia Conference, April 24, 2012http://pistoiaalliance.org
  • 2. Problem StatementGeneral Introduction (Pistoia Hanover Germany Workshop):Declining R&D productivity, rising costs of commercialization & shorterexclusivity period have driven up the average cost of launching a successfulnew drug to US $ 1.7 billion. To facilitate drug development & to lower thecost & risk of launching new drugs on their own, pharmaceutical companieshave increasingly turned to alliances for outsourcing.Screening Data / Exchange CollaborationTo respond to this challenge, large life science organizations are contributingto virtualization / externalization of R&D via various types of partnershipsbetween organizations including but not limited to outsourcing and co-sourcing assays to CROs. No standards currently exist which supportexchange of screening data within and between organizations impactingcollaboration capabilities and corresponding impacting discovery projectcycle time, cost and efficiency. 2
  • 3. Proposal and Value PropositionProposalDevise standards including but not limited to definingcommon assay result data formats and data definitions for“routine” primary, secondary in vitro pharmacology assaysgenerally outsourced by large pharmas to CROs.Value PropositionReduce discovery project hit to lead cycle time at reducedcost with improved data quality by reducing the need todevelop one off methods to exchange screening data.
  • 4. Discussion Points• Proposed starting point to select specific low IP risk discovery in vitro pharmacology assays most large pharmas outsource• Consider partnership with Society for Laboratory Automation and Screening• Leverage and extend existing standards• Start with large pharma representatives and add CRO representatives and software vendors as project progresses.Subject Matter expert resources are needed to required to work with resources Pistoia is committing to define use case scenarios and business case required to prepare a project proposal.